KR970707101A - Substituted benzylamine derivatives; A new class of neuropeptide Y1 specific ligands (CERTAIN SUBSTITUTED BENZYLAMINE DERIVATIVES; A NEW CLASS OF NEUROPEPTIDE Y1 SPECIFIC LIGANDS) - Google Patents
Substituted benzylamine derivatives; A new class of neuropeptide Y1 specific ligands (CERTAIN SUBSTITUTED BENZYLAMINE DERIVATIVES; A NEW CLASS OF NEUROPEPTIDE Y1 SPECIFIC LIGANDS)Info
- Publication number
- KR970707101A KR970707101A KR1019970702989A KR19970702989A KR970707101A KR 970707101 A KR970707101 A KR 970707101A KR 1019970702989 A KR1019970702989 A KR 1019970702989A KR 19970702989 A KR19970702989 A KR 19970702989A KR 970707101 A KR970707101 A KR 970707101A
- Authority
- KR
- South Korea
- Prior art keywords
- compound according
- phenylpiperazin
- straight
- cyclohexane
- carbon atoms
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
- C07D295/027—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring
- C07D295/033—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring with the ring nitrogen atoms directly attached to carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/14—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
- C07D317/58—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
- C07D335/02—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
본 발명은 인간의 신경펩타이드 Y1 수용체에 대한 결합력에 기인하여 비만 및 병적 기아 등의 섭식 장애, 및 본질적인 고혈압 및 울혈성 심부전 등의 심혈관계 질환을 진단하고 치료하는데 유용한 화학식(Ⅰ)의 화합물 및 약학적으로 허용가능한 이의 염을 포함한다:The present invention relates to compounds of formula (I) useful for diagnosing and treating cardiovascular diseases, such as eating disorders such as obesity and pathological starvation, and intrinsic hypertension and congestive heart failure, due to binding capacity to human neuropeptide Y1 receptor Or a pharmaceutically acceptable salt thereof:
상기 식에서 W, X, Y, A 및 T는 유기 또는 무기 치환체이고, n은 1, 2 또는 3이고, m은 2, 3 또는 4이고, R1내지 R4는 수소 또는 유기 치환체이고, B는 질소, 탄소, 황 또는 산소이다.Wherein n is 1, 2 or 3, m is 2, 3 or 4, R 1 to R 4 are hydrogen or an organic substituent, and B is Nitrogen, carbon, sulfur or oxygen.
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음Since this is a trivial issue, I did not include the contents of the text.
Claims (28)
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US33547594A | 1994-11-07 | 1994-11-07 | |
US08/335,475 | 1994-11-07 | ||
US48497495A | 1995-06-07 | 1995-06-07 | |
US47438395A | 1995-06-07 | 1995-06-07 | |
US08/474,383 | 1995-06-07 | ||
US08/484,974 | 1995-11-07 | ||
PCT/US1995/014472 WO1996014307A1 (en) | 1994-11-07 | 1995-11-07 | Certain substituted benzylamine derivatives; a new class of neuropeptide y1 specific ligands |
Publications (1)
Publication Number | Publication Date |
---|---|
KR970707101A true KR970707101A (en) | 1997-12-01 |
Family
ID=27407057
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019970702989A KR970707101A (en) | 1994-11-07 | 1995-11-07 | Substituted benzylamine derivatives; A new class of neuropeptide Y1 specific ligands (CERTAIN SUBSTITUTED BENZYLAMINE DERIVATIVES; A NEW CLASS OF NEUROPEPTIDE Y1 SPECIFIC LIGANDS) |
Country Status (13)
Country | Link |
---|---|
JP (1) | JP3386814B2 (en) |
KR (1) | KR970707101A (en) |
AU (1) | AU692977B2 (en) |
BR (1) | BR9509610A (en) |
CA (1) | CA2203878C (en) |
CZ (1) | CZ137297A3 (en) |
FI (1) | FI971931A (en) |
HU (1) | HUT78089A (en) |
NO (1) | NO972091L (en) |
NZ (1) | NZ297211A (en) |
PL (1) | PL321136A1 (en) |
SK (1) | SK57097A3 (en) |
WO (1) | WO1996014307A1 (en) |
Families Citing this family (76)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5602024A (en) | 1994-12-02 | 1997-02-11 | Synaptic Pharmaceutical Corporation | DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5) and uses thereof |
US5989920A (en) | 1994-12-02 | 1999-11-23 | Synaptic Pharmaceutical Corporation | Methods of modifying feeding behavior compounds useful in such methods and DNA encoding a hypothalmic atypical neuropeptide Y/peptide YY receptor Y5 |
WO1998003492A1 (en) * | 1996-07-23 | 1998-01-29 | Neurogen Corporation | Certain substituted benzylamine derivatives; a new class of neuropeptide y1 specific ligands |
US6849733B1 (en) | 1996-08-23 | 2005-02-01 | Agouron Pharmaceuticals, Inc. | Neuropeptide-Y ligands |
FR2754709B1 (en) * | 1996-10-23 | 1999-03-05 | Sanofi Sa | COSMETIC COMPOSITION CONTAINING AN ANTAGONIST OF GAMMA NEUROPEPTIDE RECEPTORS AND ALPHA 2 ANTAGONISTS THAT MAY BE INCORPORATED IN SUCH A COMPOSITION |
US5914329A (en) * | 1996-11-26 | 1999-06-22 | Pfizer Inc. | Dimesylate salts of neuropeptide Y ligands |
US6245817B1 (en) | 1997-02-14 | 2001-06-12 | Bayer Corporation | NPY5 receptor antagonists and methods for using same |
US6048900A (en) * | 1998-02-13 | 2000-04-11 | Bayer Corporation | Amide derivatives and methods for using the same as selective neuropeptide Y receptor antagonists |
EP0910565A1 (en) * | 1997-02-14 | 1999-04-28 | Bayer Corporation | Amide derivatives as selective neuropeptide y receptor antagonists |
US6713265B1 (en) | 1997-06-04 | 2004-03-30 | Synaptic Pharmaceutical Corporation | Methods of modifying feeding behavior, compounds useful in such methods, and DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5) |
US5889016A (en) * | 1997-06-26 | 1999-03-30 | Bristol-Myers Squibb Company | Dihydropyrimidone derivatives as NPY antagonists |
WO1999007703A1 (en) | 1997-08-05 | 1999-02-18 | Pfizer Products Inc. | 4-AMINOPYRROLE(3,2-d) PYRIMIDINES AS NEUROPEPTIDE Y RECEPTOR ANTAGONISTS |
EP0896822B1 (en) * | 1997-08-05 | 2003-03-12 | Pfizer Products Inc. | 4-Aminopyrrole (3,2-d) pyrimidines as neuropeptide Y receptor antagonists |
US6187777B1 (en) | 1998-02-06 | 2001-02-13 | Amgen Inc. | Compounds and methods which modulate feeding behavior and related diseases |
PT1027891E (en) | 1999-01-27 | 2005-04-29 | Pfizer Prod Inc | NEUROPEPTIDO ANTAGONISTA AND |
WO2000066578A1 (en) | 1999-04-30 | 2000-11-09 | Pfizer Products Inc. | Compounds for the treatment of obesity |
EP1177188B1 (en) | 1999-05-12 | 2005-10-12 | Ortho-McNeil Pharmaceutical, Inc. | Pyrazole carboxamides useful for the treatment of obesity and other disorders |
WO2000078319A1 (en) | 1999-06-21 | 2000-12-28 | Bristol-Myers Squibb Company | Dihydropyrazine derivatives as npy antagonists |
US6531478B2 (en) | 2000-02-24 | 2003-03-11 | Cheryl P. Kordik | Amino pyrazole derivatives useful for the treatment of obesity and other disorders |
JP2004516239A (en) | 2000-07-06 | 2004-06-03 | ニューロジェン コーポレイション | Melanin-concentrating hormone receptor ligand |
EP1935885A3 (en) * | 2001-05-22 | 2008-10-15 | Neurogen Corporation | Melanin concentrating hormone receptor ligands : substituted 1-benzyl-4-aryl piperazine analogues. |
CN1703401A (en) * | 2001-05-22 | 2005-11-30 | 神经原公司 | Melanin concentrating hormone receptor ligands: substituted 1-benzyl-4-aryl piperazine analogues |
DE10213051B4 (en) | 2002-03-23 | 2013-03-07 | Grünenthal GmbH | Substituted 4-aminocyclohexanols |
US7105526B2 (en) | 2002-06-28 | 2006-09-12 | Banyu Pharmaceuticals Co., Ltd. | Benzimidazole derivatives |
US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
WO2005019167A2 (en) | 2003-08-13 | 2005-03-03 | Amgen, Inc. | Melanin concentrating hormone receptor antagonist |
CN1902177A (en) | 2003-09-22 | 2007-01-24 | 万有制药株式会社 | Novel piperidine derivative |
WO2005097127A2 (en) | 2004-04-02 | 2005-10-20 | Merck & Co., Inc. | Method of treating men with metabolic and anthropometric disorders |
BRPI0518241A (en) | 2004-11-01 | 2008-04-22 | Amylin Pharmaceuticals Inc | Methods to Treat Obesity and Obesity-Related Diseases and Disorders |
US7737155B2 (en) | 2005-05-17 | 2010-06-15 | Schering Corporation | Nitrogen-containing heterocyclic compounds and methods of use thereof |
BRPI0610580B8 (en) | 2005-05-30 | 2021-05-25 | Banyu Pharma Co Ltd | piperidine derivative compound |
AU2006277253A1 (en) | 2005-08-10 | 2007-02-15 | Msd K.K. | Pyridone compound |
BRPI0614649A2 (en) | 2005-08-11 | 2011-04-12 | Amylin Pharmaceuticals Inc | hybrid polypeptides with selectable properties |
AU2006279680B2 (en) | 2005-08-11 | 2012-12-06 | Amylin Pharmaceuticals, Llc | Hybrid polypeptides with selectable properties |
AU2006282260A1 (en) | 2005-08-24 | 2007-03-01 | Msd K.K. | Phenylpyridone derivative |
JPWO2007029847A1 (en) | 2005-09-07 | 2009-03-19 | 萬有製薬株式会社 | Bicyclic aromatic substituted pyridone derivatives |
AU2006297443B2 (en) | 2005-09-29 | 2010-08-12 | Merck Sharp & Dohme Corp. | Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators |
CN101291662A (en) | 2005-10-21 | 2008-10-22 | 诺瓦提斯公司 | Combination of a renin-inhibitor and an anti-dyslipidemic agent and/or an antiobesity agent |
WO2007049798A1 (en) | 2005-10-27 | 2007-05-03 | Banyu Pharmaceutical Co., Ltd. | Novel benzoxathiin derivative |
NZ568292A (en) | 2005-11-10 | 2011-08-26 | Msd Kk | Spiro[cyclohexane-1,1'-(3'H)-4'-azaisobenzofuran]-4-carboxamide derivatives |
EP2083831B1 (en) | 2006-09-22 | 2013-12-25 | Merck Sharp & Dohme Corp. | Method of treatment using fatty acid synthesis inhibitors |
JPWO2008038692A1 (en) | 2006-09-28 | 2010-01-28 | 萬有製薬株式会社 | Diaryl ketimine derivatives |
AU2008233662B2 (en) | 2007-04-02 | 2012-08-23 | Msd K.K. | Indoledione derivative |
US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
EA020466B1 (en) | 2007-06-04 | 2014-11-28 | Синерджи Фармасьютикалз Инк. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
AU2009220605A1 (en) | 2008-03-06 | 2009-09-11 | Msd K.K. | Alkylaminopyridine derivative |
AU2009229860A1 (en) | 2008-03-28 | 2009-10-01 | Msd K.K. | Diarylmethylamide derivative having antagonistic activity on melanin-concentrating hormone receptor |
EP2810951B1 (en) | 2008-06-04 | 2017-03-15 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
US20110071129A1 (en) | 2008-06-19 | 2011-03-24 | Makoto Ando | Spirodiamine-diaryl ketoxime derivative |
ES2624828T3 (en) | 2008-07-16 | 2017-07-17 | Synergy Pharmaceuticals Inc. | Guanylate cyclase agonists useful for the treatment of gastrointestinal disorders, inflammation, cancer and others |
JPWO2010013595A1 (en) | 2008-07-30 | 2012-01-12 | Msd株式会社 | 5-membered or 5-membered or 6-membered condensed cycloalkylamine derivative |
WO2010047982A1 (en) | 2008-10-22 | 2010-04-29 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
PE20110852A1 (en) | 2008-10-30 | 2011-11-25 | Merck Sharp & Dohme | ISONICOTINAMIDE OREXIN RECEPTOR ANTAGONISTS |
CA2741672A1 (en) | 2008-10-31 | 2010-05-06 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
WO2010075068A1 (en) | 2008-12-16 | 2010-07-01 | Schering Corporation | Pyridopyrimidine derivatives and methods of use thereof |
EP2379562A1 (en) | 2008-12-16 | 2011-10-26 | Schering Corporation | Bicyclic pyranone derivatives as nicotinic acid receptor agonists |
AU2011218830B2 (en) | 2010-02-25 | 2014-07-24 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
EP3243385B1 (en) | 2011-02-25 | 2021-01-13 | Merck Sharp & Dohme Corp. | Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents |
AR088352A1 (en) | 2011-10-19 | 2014-05-28 | Merck Sharp & Dohme | ANTAGONISTS OF THE RECEIVER OF 2-PIRIDILOXI-4-NITRILE OREXINE |
JP2015525782A (en) | 2012-08-02 | 2015-09-07 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
CN104994848A (en) | 2013-02-22 | 2015-10-21 | 默沙东公司 | Antidiabetic bicyclic compounds |
WO2014139388A1 (en) | 2013-03-14 | 2014-09-18 | Merck Sharp & Dohme Corp. | Novel indole derivatives useful as anti-diabetic agents |
CA2905438A1 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase and their uses |
CA2905435A1 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Compositions useful for the treatment of gastrointestinal disorders |
PT3004138T (en) | 2013-06-05 | 2024-06-18 | Bausch Health Ireland Ltd | Ultra-pure agonists of guanylate cyclase c, method of making and using same |
WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
CA2959208C (en) | 2014-08-29 | 2023-09-19 | Tes Pharma S.R.L. | Pyrimidine derivatives and their use as inhibitors of alpha-amino-beta-carboxymuconate-epsilon-semialdehyde decarboxylase |
EP3526199B1 (en) | 2016-10-14 | 2022-04-13 | Tes Pharma S.r.l. | Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase |
US11072602B2 (en) | 2016-12-06 | 2021-07-27 | Merck Sharp & Dohme Corp. | Antidiabetic heterocyclic compounds |
US10968232B2 (en) | 2016-12-20 | 2021-04-06 | Merck Sharp & Dohme Corp. | Antidiabetic spirochroman compounds |
CA3119509A1 (en) | 2018-11-20 | 2020-05-28 | Tes Pharma S.R.L | Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxxylase |
US11098029B2 (en) | 2019-02-13 | 2021-08-24 | Merck Sharp & Dohme Corp. | 5-alkyl pyrrolidine orexin receptor agonists |
SG11202110742TA (en) | 2019-04-02 | 2021-10-28 | Aligos Therapeutics Inc | Compounds targeting prmt5 |
EP4010314B1 (en) | 2019-08-08 | 2024-02-28 | Merck Sharp & Dohme LLC | Heteroaryl pyrrolidine and piperidine orexin receptor agonists |
TW202227417A (en) | 2020-08-18 | 2022-07-16 | 美商默沙東藥廠 | Bicycloheptane pyrrolidine orexin receptor agonists |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4845221A (en) * | 1988-04-15 | 1989-07-04 | American Home Products Corporation | Serotonergic substituted piperazinyl tetralins |
ES2130116T3 (en) * | 1989-04-22 | 1999-07-01 | Wyeth John & Brother Ltd | PIPERAZINE DERIVATIVES. |
-
1995
- 1995-11-07 BR BR9509610A patent/BR9509610A/en not_active Application Discontinuation
- 1995-11-07 WO PCT/US1995/014472 patent/WO1996014307A1/en active IP Right Grant
- 1995-11-07 SK SK570-97A patent/SK57097A3/en unknown
- 1995-11-07 JP JP51549896A patent/JP3386814B2/en not_active Expired - Fee Related
- 1995-11-07 CA CA002203878A patent/CA2203878C/en not_active Expired - Fee Related
- 1995-11-07 KR KR1019970702989A patent/KR970707101A/en not_active Application Discontinuation
- 1995-11-07 PL PL95321136A patent/PL321136A1/en unknown
- 1995-11-07 HU HU9901090A patent/HUT78089A/en unknown
- 1995-11-07 CZ CZ971372A patent/CZ137297A3/en unknown
- 1995-11-07 AU AU42319/96A patent/AU692977B2/en not_active Ceased
-
1997
- 1997-04-15 NZ NZ297211A patent/NZ297211A/en unknown
- 1997-05-06 FI FI971931A patent/FI971931A/en unknown
- 1997-05-06 NO NO972091A patent/NO972091L/en unknown
Also Published As
Publication number | Publication date |
---|---|
SK57097A3 (en) | 1998-10-07 |
CA2203878C (en) | 2002-06-25 |
CA2203878A1 (en) | 1996-05-17 |
AU4231996A (en) | 1996-05-31 |
HUT78089A (en) | 1999-08-30 |
JP2001520625A (en) | 2001-10-30 |
NZ297211A (en) | 1999-01-28 |
AU692977B2 (en) | 1998-06-18 |
NO972091D0 (en) | 1997-05-06 |
BR9509610A (en) | 1997-10-28 |
FI971931A0 (en) | 1997-05-06 |
MX9703349A (en) | 1997-07-31 |
CZ137297A3 (en) | 1998-04-15 |
NO972091L (en) | 1997-07-02 |
WO1996014307A1 (en) | 1996-05-17 |
FI971931A (en) | 1997-05-06 |
JP3386814B2 (en) | 2003-03-17 |
PL321136A1 (en) | 1997-11-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR970707101A (en) | Substituted benzylamine derivatives; A new class of neuropeptide Y1 specific ligands (CERTAIN SUBSTITUTED BENZYLAMINE DERIVATIVES; A NEW CLASS OF NEUROPEPTIDE Y1 SPECIFIC LIGANDS) | |
CA2379640A1 (en) | Certain alkylene diamine-substituted heterocycles | |
KR870007888A (en) | Piperidine Derivatives and Pharmaceutical Compositions Containing the Same | |
NO20032861L (en) | Heterory urea neuropeptide Y Y5 receptor antagonists | |
DE60221098D1 (en) | CONDENSED HETEROCYCLIC DERIVATIVES | |
TR200100137T2 (en) | N-substituted aminotetralins as ligands for the neuropeptide Y Y5 receptor useful in the treatment of obesity and other disorders. | |
ATE213727T1 (en) | IN POSITION 3 1,3-DIHYDROINDOL-2-ONE DERIVATIVES SUBSTITUTED BY A NITROGEN GROUP AS VASOPRESSIN AND/OR OCYTOCIN AGONISTS AND/OR ANTAGONISTS | |
NL970034I2 (en) | Trans-6-22- (3- or 4-carbonamido-substituted pyrrol-1-y) alkyl-4-hydroxypyran-2-one as inhibitors of cholesterol synthesis. | |
DE60327097D1 (en) | DIAZINOPYRIMIDINE AND ITS USE AS PROTEIN KINASE INHIBITORS | |
EP2053041A3 (en) | 1,3,5-Trisubstituted 2(1H)-pyridones as AMPA receptor inhibitors useful for the treatment of eg Parkinson's disease | |
DE69223734D1 (en) | Condensed pyrimidine derivatives and their use as angiotensin II antagonists | |
RU2010154425A (en) | NEW URACYL COMPOUND OR ITS SALT POSSESSING INHIBITING ACTIVITY REGARDING HUMAN DESOXIURIDINTRIFOSPHATASE | |
BR0101527A (en) | Thyroid receptor ligands | |
TR200102138T2 (en) | (S) -The potassium salt of omeprazole. | |
DE69734773D1 (en) | NON-PEPTIDIC BOMBESIN RECEPTOR ANTAGONISTS | |
TR200302077T4 (en) | 2- (3,5-Bis-Trifluoromethyl-phenyl) -N-methyl-N- (6-morphonyl-4-yl-4-O-tolyl-pyridin-3-yl) -isobutyramide | |
DE69602087D1 (en) | 1-ARYL-2-ACYLAMINO-ETHAN COMPOUNDS AND THEIR USE AS A NEUROKININE, IN PARTICULAR AS A NEUROKININ-1 ANTAGONIST | |
TR199801866A1 (en) | New piperazine and piperidine compounds | |
KR910011817A (en) | Substituted cyclohexenes useful as central nervous system agents | |
TR200002037T2 (en) | E-2- [4- (4-Chloro-1,2-diphenyl-but-1-enyl) phenoxy] ethanol and its pharmaceutical compositions. | |
KR860001100A (en) | Preparation of substituted amide | |
MX9701363A (en) | 2-(piperazinyl-1-carbonylmethyl)-1,4-dihydropyridines as bradykinin antagonists. | |
DK0882038T3 (en) | Substituted N-methyl-N- (4- (piperidin-1-yl) -2- (aryl) butyl) benzamides for the treatment of allergy diseases | |
DE69906243D1 (en) | 2-indanemethanol derivatives and their use as fragrances | |
DE69332023D1 (en) | NEW PYRIDYL AND PYRIMIDYL PIPERAZINE DERIVATIVES |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E601 | Decision to refuse application |